表紙
市場調査レポート

米国のオフラベル医薬品市場と予測

United States Off-Label Drugs Market & Forecast

発行 Renub Research 商品コード 328159
出版日 ページ情報 英文 67 Pages; 16 Figures; 1 Table
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.95円で換算しております。
Back to Top
米国のオフラベル医薬品市場と予測 United States Off-Label Drugs Market & Forecast
出版日: 2015年04月13日 ページ情報: 英文 67 Pages; 16 Figures; 1 Table
概要

オフラベル使用 (適応外使用) は、米国では一般的です。米国のオフラベル医薬品に対する需要は、過去10年間で急成長を遂げ、今後も成長が見込まれています。

当レポートでは、米国のオフラベル医薬品市場について調査分析し、市場の概要、現状と予測、成長促進要因と課題などについて、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 米国のオフラベル医薬品市場と予測

第3章 米国のオフラベル医薬品市場シェアと予測

第4章 米国のオフラベル医薬品市場:セグメント別

  • 米国:がんのオフラベル医薬品市場と予測
  • 米国:中枢神経系のオフラベル医薬品市場と予測
  • 米国:抗喘息のオフラベル医薬品市場と予測
  • 米国:抗アレルギーのオフラベル医薬品市場と予測
  • 米国:抗高血圧のオフラベル医薬品市場と予測
  • 米国:抗感染のオフラベル医薬品市場と予測

第5章 一般にオフラベル処方されている医薬品

第6章 オフラベル使用薬とさまざまな視点

  • 医師の視点
  • 患者の視点
  • 製薬会社の視点
  • 規制当局の視点

第7章 虚偽請求取締法におけるオフラベル販促の和解

  • 2004年
  • 2005年
  • 2006年
  • 2007年
  • 2008年
  • 2009年
  • 2010年
  • 2011年
  • 2012年
  • 2013年
  • 2014年

第8章 米国のオフラベル医薬品市場:成長促進要因

  • 臨床診療と適応
  • 脆弱な患者人口
  • 販促改革

第9章 米国のオフラベル医薬品市場:課題

  • 規制と情報不足
  • 償還
  • 安全性と有効性
  • 生命倫理観
  • 不正確さ

図表

目次

Off-label prescribing of medicines is prevalent worldwide because it gives freedom to physicians to apply new therapeutic options based on the latest evidence. Although physicians may lawfully prescribe approved Drugs for any use consistent with available scientific data and proper medical practice, but unfortunately, this is done without adequate scientific data. Often, when the best available therapeutic option fails, patients demand new approach or new treatment which ultimately leads to off-label uses.

Off-label use is very common in United States. United States Off-label Drugs demand has grown at a fast pace in the past decade and likely to grow in the forecasting period. It is likely that United States off-label market will cross the figure of 60 Billion by the year 2020. Central Nervous System (CNS) and Cancer off-label Drugs controls the largest market share of the total US off-label Drugs market. Anti-Infectives Off-Label Drugs Market and Anti-Ashmatics Off-Label Drugs together are expected to control close to 35% market share by 2020.

Renub Research study titled “United States Off-Label Drugs Market & Forecast” report provides a comprehensive analysis of the emerging Off-Label Drugs market. The report also entails commonly prescribed Off-Label Drugs, Perspective of Physicians, Patients, Pharmaceutical Companies and Regulatory Authorities, Off-label Promotion Settlements under the False Claims Act. The report also studies Drivers and Challenges of United States Off-Label Drugs market. This 67 page report with 16 Figures and 1 Table studies 6 Off-Label Drugs Segment.

The 6 Off-Label Drugs Segment Covered in the Report are as Follows:

  • 1. Cancer Off-Label Drugs
  • 2. Central Nervous System (CNS) Off-Label Drugs
  • 3. Anti-Ashmatics Off-Label Drugs
  • 4. Anti-Allergies Off-Label Drugs
  • 5. Anti-Hypertensives Off-Label Drugs
  • 6. Anti-Infectives Off-Label Drugs

Data Sources

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Renub Research team of industry experts.

Primary sources include industry surveys and telephonic interviews with industry experts.

Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 500 paid databases.

Table of Contents

1. Executive Summary

2. United States Off-Label Drugs Market & Forecast

3. United States Off-Label Drugs Market Share & Forecast

4. United States Off-Label Drugs Market - Segment wise

  • 4.1. United States - Cancer Off-Label Drugs Market & Forecast
  • 4.2. United States - Central Nervous System (CNS) Off-Label Drugs Market & Forecast
  • 4.3. United States - Anti-Ashmatics Off-Label Drugs Market & Forecast
  • 4.4. United States - Anti-Allergies Off-Label Drugs Market & Forecast
  • 4.5. United States - Anti-Hypertensives Off-Label Drugs Market & Forecast
  • 4.6. United States - Anti-Infectives Off-Label Drugs Market & Forecast

5. Drugs Commonly Prescribed Off-Label

6. Off-Label Use of Medicine & Different Perspectives

  • 6.1. Physicians Perspective
    • 6.1.1. Physicians' Liability for Off-Label Prescriptions
  • 6.2. Patients Perspective
  • 6.3. Perspective of the Pharmaceutical Companies
  • 6.4. Perspective of Regulatory Agencies

7. Off-Label Promotion Settlements Under The False Claims Act

  • 7.1. Year 2004
  • 7.2. Year 2005
  • 7.3. Year 2006
  • 7.4. Year 2007
  • 7.5. Year 2008
  • 7.6. Year 2009
  • 7.7. Year 2010
  • 7.8. Year 2011
  • 7.9. Year 2012
  • 7.10. Year 2013
  • 7.11. Year 2014

8. United States Off-Label Drugs Market - Growth Drivers

  • 8.1. Clinical Practices and Application in the Off-Label Drugs
  • 8.2. Vulnerable Patient Populations: Information and Access
  • 8.3. Off-Label Promotion Reform

9. United States Off-Label Drugs Market - Challenges

  • 9.1. Lack of Regulation & Information of the United States Off-Label Drugs Market
  • 9.2. Reimbursement
  • 9.3. Safety and Efficacy of Unapproved and Under Evaluated Use
  • 9.4. Point of View on Bioethical Off-Label Drugs Use
  • 9.5. Inaccuracy of Off-Label Clinical Publications

LIST OF FIGURES

  • Figure 2-1: United States - Off-Label Drugs Market (Billion US$), 2011 - 2014
  • Figure 2-2: United States - Forecast for Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 3-1: United States - Off-Label Drugs Market Share (Percent), 2011 - 2014
  • Figure 3-2: United States - Forecast for Off-Label Drugs Market Share (Percent), 2015 - 2020
  • Figure 4-1: United States - Cancer Off-Label Drugs Market (Billion US$), 2008 - 2014
  • Figure 4-2: United States - Forecast for Cancer Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 4-3: United States - Central Nervous System (CNS) Off-Label Drugs Market (Billion US$), 2009 - 2014
  • Figure 4-4: United States - Forecast for Central Nervous System (CNS) Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 4-5: United States - Anti-Ashmatics Off-Label Drugs Market (Billion US$), 2010 - 2014
  • Figure 4-6: United States - Forecast for Anti-Ashmatics Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 4-7: United States - Anti-Allergies Off-Label Drugs Market (Billion US$), 2011 - 2014
  • Figure 4-8: United States - Forecast for Anti-Allergies Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 4-9: United States - Anti-Hypertensives Off-Label Drugs Market (Billion US$), 2009 - 2014
  • Figure 4-10: United States - Forecast for Anti-Hypertensives Off-Label Drugs Market (Billion US$), 2015 - 2020
  • Figure 4-11: United States - Anti-Infectives Off-Label Drugs Market (Billion US$), 2008 - 2014
  • Figure 4-12: United States - Forecast for Anti-Infectives Off-Label Drugs Market (Billion US$), 2015 - 2020

LIST OF TABLES

  • Table 5-1: Commonly Prescribed Off-Label Drugs
Back to Top